Moderna (MRNA), with its widely used COVID-19 vaccine, rose to prominence during the global pandemic. The stock soared an eye ...

(NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the ...

Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in ...

Over the last year, Noubar Afeyan has watched Cambridge-based Moderna go from perhaps the world’s most celebrated company to a target of government officials promoting falsehoods about mRNA technology ...

Cancer patients who received the mRNA-based jab after starting immunotherapy lived significantly longer than those who did ...

CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its ...

The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients – revving up their immune ...

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event – Analyst Day at 9:00 a.m. ET on Thursday, November 20, 2025. The ...

It's a significant setback for the Cambridge company, which is already facing pressure from Wall Street and the federal government.

October 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 6, 2025 to report its third quarter 2025 ...

To tailor cancer therapies to individual patients, Moderna, BioNTech and other companies are rethinking how they optimize ...